ESMO 2024: Invited Discussant: Optimizing Post-IO Therapy in Clear Cell RCC and ...
Dr. Manuela Schmidinger discussed three abstracts at the 2024 ESMO meeting on kidney cancer, focusing on the TiNivo-2, LITESPARK-005, and SUNNIFORECAST trials. TiNivo-2 found no superiority of tivozanib + nivolumab over tivozanib monotherapy in RCC patients post-IO therapy. LITESPARK-005 showed belzutifan maintained progression-free survival over everolimus but lacked overall survival benefit. SUNNIFORECAST indicated nivolumab + ipilimumab improved overall survival in non-clear cell RCC compared to standard care, though with trial heterogeneity challenges.
Reference News
Dr. Manuela Schmidinger discussed three abstracts at the 2024 ESMO meeting on kidney cancer, focusing on the TiNivo-2, LITESPARK-005, and SUNNIFORECAST trials. TiNivo-2 found no superiority of tivozanib + nivolumab over tivozanib monotherapy in RCC patients post-IO therapy. LITESPARK-005 showed belzutifan maintained progression-free survival over everolimus but lacked overall survival benefit. SUNNIFORECAST indicated nivolumab + ipilimumab improved overall survival in non-clear cell RCC compared to standard care, though with trial heterogeneity challenges.